Better Therapeutics, Inc. BTTX
At closeNov 2, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 5.45K
- EPS (ttm)
- -0.37
- Shares out
- 54.52M
- Forward P/E
- -0.01
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 500
- Avg volume
- 4.18K
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0002
- Beta
- 2.13
- Analysts
- Buy
- Price target
- 5.25 (+5249900.0%)
- Earnings date
- Dec 26, 2024
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 8.18M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.56M
- Total cash
- 6.60M
- Total debt
- 14.31M
- Return on equity
- 0.00%
- Short % of float
- 6.21%
- 50-day average
- 0.11514
- 200-day average
- 0.349255
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 5.25
- Target (high)
- 9.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate -0.12.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 2, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 4, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.15 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -0.39 | -0.24 | +0.15 | +38.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2023 | Chardan Capital | reit | Buy | Buy |
| Aug 9, 2023 | Lake Street | main | Buy | Buy |
| Apr 13, 2023 | Lake Street | main | — | Buy |
| Mar 30, 2023 | Chardan Capital | main | — | Buy |
| Nov 14, 2022 | Chardan Capital | main | — | Buy |
| Jul 28, 2022 | Chardan Capital | main | — | Buy |
About Better Therapeutics, Inc.
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bettertx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BTTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMANINO ANDREW J | Director | Stock Award(Grant) | Dec 17, 2023 | 745,452 |
| BERMAN MARK A | Officer | Stock Award(Grant) | Dec 17, 2023 | 448,140 |
| CARMONA RICHARD H. M.D. | Director | Stock Award(Grant) | Dec 17, 2023 | 157,369 |
| GRANGER ELDER | Director | Stock Award(Grant) | Dec 17, 2023 | 39,601 |
| KARBE FRANK L | Chief Executive Officer | Stock Award(Grant) | Dec 17, 2023 | 526,516 |
| LAVIZZO-MOUREY RISA J | Director | Stock Award(Grant) | Dec 17, 2023 | 13,750 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.08% | 438,479 | 473.56K | Jun 29, 2023 |
| Farallon Capital Management Llc | 0.81% | 330,619 | 357.07K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.30% | 121,724 | 131.46K | Jun 29, 2023 |
| Blackrock Inc. | 0.22% | 90,390 | 97.62K | Jun 29, 2023 |
| State Street Corporation | 0.11% | 45,200 | 48.82K | Jun 29, 2023 |
| Ameriprise Financial, Inc. | 0.04% | 15,000 | 16.20K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.80% | 326,043 | 352.13K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.28% | 112,436 | 121.43K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.08% | 32,063 | 22.45K | May 30, 2023 |
| iShares Micro Cap ETF | 0.08% | 30,928 | 19.18K | Aug 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 13,172 | 9.22K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 6,986 | 4.89K | May 30, 2023 |